Want to see TSE:VXL full AI Analyst Report?
VXL Stock Chart & Stats
C$0.17
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.17
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
C$657.36K
Enterprise ValueC$0.07
Total Cash (Recent Filing)C$527.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)1.2
Beta-1.06
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet materially lowers solvency and interest-cost risk for an early-stage biotech, preserving flexibility to pursue clinical programs or partnerships and reducing near-term cash outflows. This durability supports runway and strategic optionality over months.
Clinical-stage Immunotherapy FocusA platform focused on immunotherapy and T‑cell mechanisms targets structurally growing areas like oncology and infectious disease. This strategic focus can sustain long-term partner interest and licensing potential, aligning the company with enduring scientific and market tailwinds.
Improving Cash Burn TrendYear-over-year improvement in cash burn suggests stronger cost control and operational discipline. Continued reduction in negative cash flow extends runway and reduces reliance on immediate financings, improving the company's capacity to advance trials over the next several months.
Bears Say
No Revenue / Pre-revenueAbsence of commercial revenue means the company remains dependent on external financing or partnerships to fund operations. This structural lack of operating cash generation elevates execution and financing risk and makes multi-quarter program funding contingent on capital markets or deals.
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow depletes liquidity and forces dilution or debt raises to fund R&D and trials. Even with improvement, ongoing negative FCF constrains strategic choices, pressures timelines, and magnifies the impact of any clinical setbacks on funding needs.
Volatile, Low-quality Net IncomeReported positive net income driven by non-operating items while core EBIT remains negative signals low earnings quality. This volatility reduces predictability of financial performance and makes it harder to rely on reported profits when assessing sustainable cash generation or operational progress.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.29 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$657.36K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 8 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Currently, no data Available
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,021 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―